ARDELYX, INC.
ARDELYX, INC. (ARDX): 11 pipeline candidates · 6 upcoming catalysts · ~25 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
25.2 months
D/E 2.39 · 0% dilution
Lead: Approved
11 candidates
6 upcoming, next in ~75d
1 buy · 48 sells (180d)
A transparent, data-derived signal for ARDELYX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.4B
Cash
$31.2M
Quarterly Burn
$32.2M
Runway
25.2 mo
Revenue
$94.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| IBSRELA | Approved |
| Portfolio of TGR5 agonist compounds | — |
| RDX013 | Phase 2 |
| RDX020 | Preclinical |
| RDX10531 | Preclinical |
| tenapanor | Phase 2 |
| tenapanor (CIC label extension / ACCEL (ten-03-301)) | Phase 3 |
| tenapanor 25 mg bid | Phase 3 |
| tenapanor 5 mg bid | Phase 3 |
| tenapanor 50 mg bid | Phase 3 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
236
Total value held
$1.09B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 21,164,132 | $126.8M |
| vanguard capital management llc | 20,731,024 | $124.2M |
| millennium management llc | 18,043,970 | $108.1M |
| janus henderson group plc | 16,742,468 | $100.3M |
| state street corp | 13,604,307 | $81.5M |
| nomura asset management international inc. | 8,169,369 | $48.9M |
| vanguard portfolio management llc | 6,661,693 | $39.9M |
| geode capital management, llc | 6,007,455 | $36.0M |
| two sigma investments, lp | 4,274,043 | $25.6M |
| citadel advisors llc | 3,763,774 | $22.5M |
Showing top 10 of 236 institutional holders of ARDELYX, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARDELYX, INC.'s pipeline?
ARDELYX, INC. (ARDX) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARDELYX, INC.'s lead drug candidate?
ARDELYX, INC.'s most advanced tracked candidate is IBSRELA (Approved) for Irritable bowel syndrome with constipation (IBS-C) in adults.
What is ARDELYX, INC.'s next catalyst?
ARDELYX, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Effi" — expected September 1, 2026.
What is ARDELYX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARDELYX, INC. has approximately 25.2 months of cash runway.
What is ARDELYX, INC.'s market capitalization?
ARDELYX, INC.'s market capitalization is approximately $1.4B.
Get the full picture on ARDELYX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.